Brand Name
Ztalmy
Generic Name
Ganaxolone
View Brand Information FDA approval date: June 06, 2022
Classification: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator
Form: Suspension
What is Ztalmy (Ganaxolone)?
ZTALMY is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients 2 years of age and older. ZTALMY is a neuroactive steroid gamma-aminobutyric acid A receptor positive modulator indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder in patients 2 years of age and older.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment